目的 探讨达格列净辅助治疗老年心力衰竭合并2型糖尿病(T2DM)患者的效果。方法 将我院2020年9月—2022年2月期间收治的82例老年心力衰竭合并T2DM患者按照随机数字表法分为观察组和对照组,对照组41例予以常规降糖及抗心力衰竭药物治疗,观察组41例在对照组基础上予以达格列净治疗,观察2组患者血糖水平、心肌损伤标志物、心室结构以及不良反应。结果 治疗3个月后,观察组空腹血糖、餐后2小时血糖、糖化血红蛋白水平低于对照组(P<0.05);观察组NT-proBNP、AngⅡ水平低于对照组(P<0.05);观察组LAVI、LVESd、LVEDd低于对照组,观察组LVEF高于对照组(P<0.05);观察组不良反应发生率(12.20%)与对照组(7.32%)对比差异无统计学意义(P>0.05)。结论 达格列净辅助治疗老年心力衰竭合并T2DM患者有效降低血糖,减轻心肌损伤,改善心脏结构和功能,且不增加患者不良反应发生率。

目的 分析心力衰竭伴快速心房颤动(简称:心衰伴快速房颤)患者接受胺碘酮急诊抢救治疗的效果及对24 h心室率的影响。方法 将2017年1月—2020年12月急诊接诊且行西地兰治疗的60例心衰伴快速房颤患者作为对照组,将同期急诊接诊且行胺碘酮治疗的60例心衰伴快速房颤患者作为观察组,对组间心功能指标、炎症因子水平、心室率、临床疗效、药物不良反应展开分析。结果 ①组间心功能指标、炎症因子水平在治疗前无差异,P>0.05;观察组心功能指标、炎症因子水平在治疗后优于对照组,P<0.05;②组间心室率在治疗前无差异,P>0.05;观察组治疗后4 h、12 h、24 h心室率均低于对照组,P<0.05;③观察组5例无效(8.33%),对照组14例无效(23.33%),P<0.05;④观察组药物不良反应率(3.33%)与对照组药物不良反应率(5.00%)无差异,P>0.05。结论 在急诊抢救心衰伴快速房颤患者时采用胺碘酮,可以改善患者心功能、炎症反应、心室率,加之无明显不良反应,值得推广。

Objective To analyze the efficacy of emergency treatment with amiodarone and its influence on 24-hour ventricular rate in patients with heart failure and rapid atrial fibrillation. Methods From January 2017 to December 2020, 60 patients with heart failure and rapid atrial fibrillation who received emergency treatment and cedilanide treatment were selected as the control group, and 60 patients with heart failure and rapid atrial fibrillation who received emergency treatment and amiodarone treatment at the same period were selected as the observation group. Results ① There was no significant difference in cardiac function index and inflammatory factors level between the two groups before treatment, P>0.05.The cardiac function index and inflammatory factors level of the observation group were more improved than those of the control group after treatment, P<0.05. ② There was no significant difference in ventricular rate between the two groups before treatment, P>0.05.The ventricular rates of the observation group at 4 h, 12 h and 24 h after treatment were lower than those of the control group, P< 0.05. ③ Treatment for 5 cases (8.33%) in the observation group, 14 cases (23.33%) in the control group were ineffective, P<0.05. ④ There was no significant difference in the adverse drug reaction incidence between the observation group (3.33%) and the control group (5.00%), P>0.05. Conclusion Amiodarone could improve the cardiac function, inflammatory reaction and ventricular rate of patients with heart failure and rapid atrial fibrillation in emergency treatment, and there was no obvious adverse reaction, so it is worthy of promotion.

目的 分析基于微信平台步行运动训练对慢性充血性心力衰竭(CHF)患者心脏康复水平的影响。方法 本次研究对象来源于梅州市中医医院一内科2020年11月—2021年12月住院的90例CHF患者,根据随机数字表法分组(每组n=45),对比组给予常规药物治疗,观察组在对比组基础上给予基于微信平台步行运动训练治疗,对比两组临床疗效、心脏功能指标、血清NT-proBNP、D-D、6分钟步行距离、日常生活能力评分、明尼苏达心力衰竭生活质量调查表(MLHFQ)评分。结果 观察组临床总有效率(95.56%)高于对比组(66.67%),观察组治疗后左心室舒张末期内径、左心室收缩末期内径均低于对比组,观察组治疗后左室射血分数高于对比组,观察组治疗后血清NT-proBNP、D-D均低于对比组,观察组治疗后6分钟步行距离、日常生活能力评分均高于对比组,观察组治疗后MLHFQ评分低于对比组,P＜0.05(差异均具有统计学意义)。结论 基于微信平台步行运动训练可有效改善CHF患者心功能,抑制NT-proBNP、D-D高表达,提高日常生活能力、生存质量。

Objective To analyze the effect of walking training through Wechat on cardiac rehabilitation of chronic congestive heart failure (CHF) patients. Methods A total of 90 patients with CHF hospitalized in the First Internal Medicine Department of Meizhou Traditional Chinese Medicine Hospital from November 2020 to December 2021 were enrolled in this study. They were divided into two groups according to the random number table method (45 patients in each group).The control group was given routine drug treatment,and the observation group was given walking training through Wechat on the basis of control group. The clinical efficacy,cardiac function indexes,serum NT-proBNP,D-D levels,6-minute walking distance,ability of daily life (ADL) score and Minnesota Living with Heart Failure Questionnaire (MLHFQ) score were compared between two groups. Results The total clinical effective rate of the observation group (95.56%) was higher than that of the control group (66.67%),the LVEDd and LVESd of the observation group were lower than those of the control group after treatment,the LVEF of the observation group was higher than that of the control group after treatment,the serum NT-proBNP and D-D levels of the observation group were lower than those of the control group after treatment,the 6-minute walking distance and ADL score of the observation group were higher than those of the control group after treatment,and the MLHFQ score of the observation group was lower than that of the control group after treatment,P<0.05 (the difference was statistically significant).Conclusions Walking training by Wechat could effectively improve the cardiac function of CHF patients,inhibit the high expression of NT proBNP and D-D,and improve the ability of daily living and quality of life.

目的 探讨生脉注射液联合环磷腺苷治疗慢性心力衰竭的临床疗效及对其心功能的影响。方法 选择本院2016年3月—2017年4月收治的90例慢性心力衰竭患者,随机将其分为2组,各45例。对照组采用环磷腺苷静脉滴注治疗,在此基础上观察组加用生脉注射液治疗,比较两组临床疗效、心功能及药物不良反应。结果 2个疗程后,观察组总有效率、LVEF、CI及CO水平均较对照组高,差异有统计学意义(P＜0.05);两组治疗期间药物不良反应率相比,差异无统计学意义(P＞0.05)。结论 生脉注射液联合环磷腺苷可提高慢性心力衰竭临床疗效,改善心功能,且用药安全性较高。

目的 探究曲美他嗪对慢性心力衰竭患者血清炎症因子水平及心功能的影响。方法 选择2015年4月—2016年3月我院收治的慢性心力衰竭患者94例,根据随机数表法分为两组,每组47例。对照组实施阿托伐他汀治疗,观察组在此基础上予以曲美他嗪治疗。比较两组患者治疗6个月后血清炎症因子和脑利钠肽(BNP)、心功能以及临床疗效。结果 观察组血清C-反应蛋白(CRP)、BNP、肿瘤坏死因子-α(TNF-α)水平均低于对照组,差异有统计学意义(P＜0.05);观察组左收缩末期内径(LVESD)、左室舒张末期内径(LVEDd)水平较对照组明显降低,而左室射血分数(LVEF)高于对照组,差异有统计学意义(P＜0.05);观察组患者治疗有效率与对照组相比明显提高,差异有统计学意义(P＜0.05)。结论 对慢性心力衰竭患者实施曲美他嗪治疗,能有效提高患者临床疗效,降低患者血清炎症因子,改善心功能,值得临床推广与应用。

Objective To investigate the effect of Trimetazidine on serum inflammatory factors levels and cardiac function in patients with chronic heart failure (CHF). Methods 94 CHF patients admitted into our hospital from April 2015 to March 2016 were divided into two groups randomly, 47 cases in each. Control group took Atorvastatin, and on this basis observation group was given Trimetazidine. The serum inflammatory factors levels, brain natriuretic peptide (BNP), cardiac function and clinical efficacy of two groups after treatment for 6 months were compared. Results The serum C-reactive protein (CRP), BNP, Tumor necrosis factor-α (TNF-α) levels of observation group were lower than control group (P<0.05); The left ventricular end-systolic diameter (LVESD), Left ventricular end-diastolic diameter (LVEDd) levels of observation group significantly decreased compared with control group, but left ventricular ejection fraction (LVEF) was higher than control group (P<0.05); The curative effective rate of observation group significantly increased compared with control group (P<0.05). Conclusion Trimetazidine for treating CHF patients may effectively increase clinical efficacy, decrease serum inflammatory factors and improve cardiac function, which is worthy of clinical promotion and application.

目的 对比双腔耐高压PICC和股静脉置管在IV级心力衰竭患者中的应用效果。方法 选取我院 2016年1月—12月收治的端坐位IV级心力衰竭患者61例,按照便利抽样的方法将其随机分成研究组31例和对照组30例。研究组患者行耐高压PICC置管,对照组患者行双腔中心股静脉置管,观察2组患者的一次性置管成功率、导管头端位置、并发症发生率、留置导管天数和患者满意度等相关临床指标。结果 研究组患者的一次插管成功率为 93.55%(29例),高于对照组的83.33%(25例)(P<0.05);研究组患者的并发症发生率低于对照组(P<0.05)。结论 对IV级心力衰竭患者在端坐位下予以耐高压PICC 插管进行治疗,能提高一次置管成功率,降低并发症发生率,提高患者满意度,可作为患者抢救时的首选静脉通道。

Objective To compare the effect of dual chamber high pressure PICC (peripherally inserted central catheter) and femoral vein CVC(central venous catheter)catheterization in patients with IV class heart failure. Methods From January to December 2016, 61 patients with congestive heart failure in the sitting position were selected from our hospital. According to the convenient sampling method, they were randomly divided into the study group (31 cases) and the control group(n=30). The study group were treated with high pressure PICC tube, the control group underwent femoral vein catheterization. Two groups of patients with the success rate of catheterization, catheter tip location, complications, indwelling catheter days and related clinical indicators of patient satisfaction were observed. Results The successful rate of intubation in the study group was 93.55% (29 cases), higher than that of the control group (25 cases)(P<0.05), and the incidence of complications in the study group was lower than that of the control group(P<0.05)(83.33%). Conclusion Treatment for patients with heart failure IV be in sitting position under high pressure PICC intubation, may improve the success rate of catheterization, reduce the incidence of complications, improve patient satisfaction, and be the first choice when the rescue of patients with venous channel.

目的 观察真武四物汤足浴治疗阳虚血瘀型慢性心力衰竭(CHF)的临床疗效。方法 72例心功能Ⅱ-Ⅲ患者按随机数字表法分为治疗组(36例)和对照组(36例),对照组给予心衰常规治疗。治疗组在心衰常规治疗基础上加用真武四物汤足浴,每次30分钟,每日2次,共治疗4周。观察治疗后6 min步行距离改善情况。结果 治疗组心功能和中医症候总有效率分别为88.89%和94.44%,对照组总有效率分别为69.44%和66.67%,两组比较差异(P＜0.01或P＜0.05);两组治疗前后6 min步行距离比较差异(P＜0.05);两组治疗后6 min步行距离比较差异有统计学意义(P＜0.01)。结论 在常规治疗的基础上联合真武四物汤足浴,可以改善阳虚血瘀型慢性心力衰竭患者的临床症状,提高运动耐量,促进心力衰竭患者的康复。

目的 通过建立急性心力衰竭（AHF）患者服药依从性预测模型,提高AHF患者的服药依从性和临床管理效果。方法 纳入2021年1月—2023年12月在广州市番禺区何贤纪念医院住院治疗的580例AHF患者,通过收集患者的一般人口学资料、疾病相关资料及出院后6个月的服药依从性数据,应用Logistic回归模型分析患者服药依从性的影响因素,并基于影响因素建立预测模型。结果 患者服药依从性总体良好（75%）。依从性良好组与依从性差组的年龄、独居情况、合并基础病、服药种类、疾病了解评分、治疗信心评分和自我控制信心评分比较差异有统计学意义（P<0.05）。Logistic 回归分析显示危险因素包括年龄≥60岁（OR=1.774）、独居（OR=1.871）、合并基础病≥2种（OR=1.719）和服药种类≥7种（OR=1.456）。而疾病了解评分（OR=0.923）、治疗信心评分（OR=0.946）和自我控制信心评分（OR=0.901）是保护因素（P<0.05）。基于上述因素建立的预测模型,通过ROC曲线验证,曲线下面积为0.815（95%CI：0.780~0.850）,提示所构建的模型具有良好的区分度。对该模型的校准度进行评价,P=0.528,提示该预测模型拟合度良好。此外,该预测模型的一致性指数为0.738,说明模型的预测性能良好。绘制的决策曲线中,曲线位于极端线之上,当阈概率取值在9%~59%时,对应的净获益率为0~27%,提示建立的模型具有优秀的临床有效性。结论 AHF患者的服药依从性受到多种因素的影响,包括年龄、居住状态、合并基础病种类及服药种类等。

Objective To establish a predictive model for medication compliance among acute heart failure（AHF）patients in order to enhance their therapeutic compliance and optimize clinical outcomes. Methods A total of 580 AHF inpatients at He Xian Memorial Hospital in Panyu District, Guangzhou between January 2021 and December 2023 were enrolled. Demographic information, disease-specific data,as well as post-discharge medication compliance records within six-month were collected by investigators. Utilizing logistic regression analysis revealed several influential determinants affecting medication compliance which formed the basis for constructing our predictive model. Results Generally,patient compliance was good（75%）. The comparison between the good compliance group and the poor compliance group showed that there were significant differences in age, living alone,combined with underlying diseases, types of medication, disease understanding score, treatment confidence score and self-control confidence score（P<0. 05）. Logistic regression analysis showed that independent risk indicators including individuals aged ≥60 years（odds ratio[OR]=1. 774）, those living alone（OR=1. 871）, presence of two or more underlying diseases（OR=1. 719）, along with consumption of seven or more medications daily（OR=1. 456）. Conversely,disease awareness score（OR=0. 923）, treatment confidence score（OR=0. 946）, and self-control confidence score（OR=0. 901）were identified as independent protective factors. Validation using receiver operating characteristic curves demonstrated robust predictive performance with an area under curve value of 0. 815（95%CI：0. 780-0. 850）, affirming its efficacy. The calibration of the model was evaluated, with a P-value of 0. 528, indicating good fit of the predictive model. Additionally, the concordance index（C-index）of the model was 0. 738, suggesting its excellent predictive performance. The decision curve analysis revealed that the curve was above the extreme lines, with a net benefit rate ranging from 0 to 27% when the threshold probability falls between. Conclusions The medication compliance of AHF patients is influenced by various factors, including age, living arrangement, the number of underlying diseases, and the number of medications taken. Targeted interventions such as enhancing patient education, simplifying treatment regimens, and improving social support can effectively improve the medication compliance of AHF patients. The predictive model established in this study provides a scientific basis for clinicians to develop more precise and effective individualized intervention measures,thereby improving the prognosis and quality of life.

        目的   分析达格列净联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭（HFrEF）效果。方法  连续抽取2021年1月—2023年6月在广州市第一人民医院心内科住院的射血分数降低的心力衰竭（HFrEF）患者203例，随访至少6个月，按照接受的治疗进行分组。对照组予常规治疗和沙库巴曲缬沙坦治疗；观察组予常规治疗、沙库巴曲缬沙坦和达格列净治疗；对比两组疗效，观察指标包括住院时间，入院及出院后6个月的心功能状态（NYHA纽约心脏病协会心功能分级）、心脏超声指标左室射血分数（LVEF）、左室舒张末内径（LVEDD）、左室收缩末内径（LVSDD）、血液指标-端脑钠肽前体（NT-proBNP N）、糖化血红蛋白（HBA1c）、血肌酐（Cr）、6个月时的再住院率及全因死亡率。结果   观察组心脏监护病房（CCU）停留时间（2.54±1.26）d，短于对照组的（3.73±1.21）d；观察组6个月时观察组心功能NYHA改善≥2级比例为95.05%高于对照组的86.27%，差异有统计学意义（P＜0.05）；观察组6个月时的LVEDD、LVESD水平分别为（48.22±7.35）（34.61±4.32）mm，低于对照组的（51.47±8.02）（43.07±5.33）mm，LVEF为（51.49±5.40）%，高于对照组的（46.18±4.21）%，差异有统计学意义（P＜0.05）；6个月时观察组的NT-proBNP为（415.58±31.57）pg/mL，低于对照组的（520.23±385.56）pg/mL，差异有统计学意义（P＜0.05）；两组的住院时间、血清肌酐（Cr）、HBA1c、6个月时的再住院率、全因病死率对比，差异不显著（P＞0.05）。观察组HBA1c值为（6.04±0.66）mmol/L，高于对照组的（5.20±0.56）mmol/L（P＜0.05）。结论  HFrEF患者采取达格列净+沙库巴曲缬沙坦治疗，可通过协同作用，缩短CCU停留时间，改善患者6个月时的心功能状态，降低NT-proBNP值，减少心脏扩大趋势，提高LVEF水平。

       Objective  To analyze the efficacy of  dapagliflozin combined with  sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction（HFrEF）．Methods  A total of 203 patients with HFrEF who were hospitalized in the cardiology department of the hospital between January 2021 and June 2023 were enrolled and followed up for at least six months．Patients were divided into groups based on their treatment regimens：the control group received conventional treatment plus sacubitril/valsartan，while the observation group received conventional treatment plus sacubitril/valsartan and dapagliflozin．The two groups were compared for clinical outcomes，including length of hospital stay，cardiac function（NYHA classification）at admission and six months after discharge，echocardiographic indicators（LVEF，LVEDD，LVESD），blood indicators（NT-proBNP，HbA1c，creatinine），six-month rehospitalization rate，and all-cause mortality．Results  The observation group had a shorter CCU stay（2.54±1.26 days）compared to the control group（3.73±1.21 days）．At sixth month，the proportion of patients in the observation group with an NYHA improvement ≥2 grades（95.05%）was significantly higher than that in the control group（86.27%）（P＜0.05）．The observation group demonstrated lower LVEDD（48.22±7.35 mm）and LVESD（34.61±4.32 mm）levels and higher LVEF（51.49±5.40%）compared to the control group（LVEDD：［51.47±8.02］ mm，LVESD：［43.07±5.33］mm，LVEF：［46.18±4.21］%）（P＜0.05）．NT-proBNP levels in the observation group（［415.58±31.57］ pg/mL）were significantly lower than those in the control group（［520.23±385.56］ pg/ml）（P＜0.05）．There were no significant differences between the two groups in length of total hospital stay，serum creatinine，HbA1c，six-month rehospitalization rate，or all-cause mortality（P＞0.05）．However，HbA1c levels in the observation group（［6.04±0.66］ mmol/L）were higher than those in the control group（［5.20±0.56］ mmol/L）（P＜0.05）．Conclusions  The combination of dapagliflozin and sacubitril/valsartan in the treatment of HFrEF patients can exert a synergistic effect，shorten CCU stay，improve cardiac function at sixth month，reduce NT-proBNP levels，mitigate cardiac dilation，and increase LVEF．

       目的   探究血清多配体蛋白聚糖-1（SCD-1）与可溶性血管内皮生长因子受体-2（sVEGFR-2）表达水平在老年慢性心力衰竭患者预后评估的判定价值。方法   选取2023年1月—2024年3月珠海市第五人民医院检验科收治的110例老年慢性心力衰竭患者，检测其血清SCD-1和sVEGFR-2水平，对患者进行随访调查，了解其再次由于心力衰竭住院、心源性死亡的情况。运用多因素Logistic回归分析，探究老年慢性心力衰竭患者预后影响因素。结果  Logistic回归分析显示，心功能分级（OR=3.433，95%CI：0.934~6.431）、B型脑钠肽升高（OR=2.462，95%CI：0.861~4.765）、血清SCD-1升高（OR=3.795，95%CI：0.972~6.894）、血清sVEGFR-2升高（OR=3.842，95%CI：0.942~6.912）为影响老年慢性心力衰竭患者预后不良的重要因素（P＜0.05）；联合血清SCD-1和sVEGFR-2曲线下面积0.962与B型脑肽钠曲线下面积0.844，相较于单一SCD-1曲线下面积0.658、sVEGFR-2曲线下面积0.712明显偏高（P＜0.05）。结论   经研究证实，老年慢性心力衰竭患者预后效果不理想，其血清SCD-1和sVEGFR-2监测水平异常升高，和老年慢性心力衰竭预后不佳存在关联性，可视为老年慢性心力衰竭患者判定预后效果的主要标志物。

      Objective  To investigate the prognostic value of serum syndecan-1（SCD-1）and soluble vascular endothelial growth factor receptor-2（sVEGFR-2）expression levels in elderly patients with chronic heart failure．Methods  A total of 110 elderly patients with chronic heart failure admitted to our hospital were selected，with a time interval of January 2023 to March 2024．Serum SCD-1 and sVEGFR-2 levels were detected and follow-up investigations were conducted to understand their re hospitalization and cardiogenic death due to heart failure．Multiple logistic  regression analysis was used to explore the prognostic factors affecting elderly patients with chronic heart failure．Results  According to logistic retrospective analysis，heart function grading（OR=3.433，95%CI：0.934-6.431），elevated B-type brain natriuretic peptide（OR=2.462，95%CI：0.861-4.765），elevated serum SCD-1（OR=3.795，95%CI：0.972-6.894），and elevated serum sVEGFR-2（OR=3.842，95%CI：0.942-6.912）were important factors affecting the poor prognosis of elderly patients with chronic heart failure，with differences P＜0.05．The area under the curve of combined serum SCD-1 and sVEGFR-2 was 0.962，and the area under the curve of B-type brain peptide sodium was 0.844，which was significantly higher than that of a single SCD-1 curve of 0.658 and sVEGFR-2 curve of 0.712，with a difference of P＜0.05．Conclusions  Research has confirmed that the prognosis of elderly patients with chronic heart failure is not satisfied，and their serum SCD-1 and sVEGFR-2 monitoring levels are abnormally elevated，which is related to the poor prognosis of elderly patients with chronic heart failure．It can be regarded as the main biomarker for defining the prognosis of elderly patients with chronic heart failure．